Ormeloxifene is also licensed for use as a treatment for dysfunctional uterine bleeding, and there is speculation that it may be useful in the treatment of breast cancer.
Ormeloxifene is also licensed for use as a treatment for dysfunctional uterine bleeding, under the trade name Sevista. There is speculation that ormeloxifene may be useful in the treatment of breast cancer.